Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma

Benjamin L Maughan; Neeraj Agarwal; Syed A Hussain; Kenneth M Boucher; Hans Von Der Maase; Donald S Kaufman; Vito Lorusso; Malcolm J Moore; Matthew D Galsky; Guru Sonpavde

doi:10.1016/j.clgc.2012.12.007

Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma

Benjamin L Maughan, Neeraj Agarwal, Syed A Hussain, Kenneth M Boucher, Hans Von Der Maase, Donald S Kaufman, Vito Lorusso, Malcolm J Moore, Matthew D Galsky, Guru Sonpavde

6 Citations (Scopus)

Abstract

Weekly gemcitabine with GC every 3-4 weeks is considered conventional first-line chemotherapy for advanced urothelial carcinoma (UC). Weekly split-dose cisplatin with wGC might be less toxic and have similar activity, but has not been compared with GC. We pooled published phase II trials of GC and wGC to compare efficacy and safety.

Original language	English
Journal	Clinical Genitourinary Cancer (Online)
Volume	11
Issue number	3
Pages (from-to)	316-20
Number of pages	5
ISSN	1938-0682
DOIs	https://doi.org/10.1016/j.clgc.2012.12.007
Publication status	Published - Sept 2013

Access to Document

10.1016/j.clgc.2012.12.007

Cite this

Maughan, B. L., Agarwal, N., Hussain, S. A., Boucher, K. M., Von Der Maase, H., Kaufman, D. S., Lorusso, V., Moore, M. J., Galsky, M. D., & Sonpavde, G. (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clinical Genitourinary Cancer (Online), 11(3), 316-20. https://doi.org/10.1016/j.clgc.2012.12.007

Maughan, BL, Agarwal, N, Hussain, SA, Boucher, KM, Von Der Maase, H, Kaufman, DS, Lorusso, V, Moore, MJ, Galsky, MD & Sonpavde, G 2013, 'Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma', Clinical Genitourinary Cancer (Online), vol. 11, no. 3, pp. 316-20. https://doi.org/10.1016/j.clgc.2012.12.007

@article{a66f85d8ff404c14b9389e817936aa1f,

title = "Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma",

abstract = "Weekly gemcitabine with GC every 3-4 weeks is considered conventional first-line chemotherapy for advanced urothelial carcinoma (UC). Weekly split-dose cisplatin with wGC might be less toxic and have similar activity, but has not been compared with GC. We pooled published phase II trials of GC and wGC to compare efficacy and safety.",

author = "Maughan, \{Benjamin L\} and Neeraj Agarwal and Hussain, \{Syed A\} and Boucher, \{Kenneth M\} and \{Von Der Maase\}, Hans and Kaufman, \{Donald S\} and Vito Lorusso and Moore, \{Malcolm J\} and Galsky, \{Matthew D\} and Guru Sonpavde",

year = "2013",

month = sep,

doi = "10.1016/j.clgc.2012.12.007",

language = "English",

volume = "11",

pages = "316--20",

journal = "Clinical Genitourinary Cancer (Online)",

issn = "1938-0682",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma

AU - Maughan, Benjamin L

AU - Agarwal, Neeraj

AU - Hussain, Syed A

AU - Boucher, Kenneth M

AU - Von Der Maase, Hans

AU - Kaufman, Donald S

AU - Lorusso, Vito

AU - Moore, Malcolm J

AU - Galsky, Matthew D

AU - Sonpavde, Guru

PY - 2013/9

Y1 - 2013/9

N2 - Weekly gemcitabine with GC every 3-4 weeks is considered conventional first-line chemotherapy for advanced urothelial carcinoma (UC). Weekly split-dose cisplatin with wGC might be less toxic and have similar activity, but has not been compared with GC. We pooled published phase II trials of GC and wGC to compare efficacy and safety.

AB - Weekly gemcitabine with GC every 3-4 weeks is considered conventional first-line chemotherapy for advanced urothelial carcinoma (UC). Weekly split-dose cisplatin with wGC might be less toxic and have similar activity, but has not been compared with GC. We pooled published phase II trials of GC and wGC to compare efficacy and safety.

UR - https://www.scopus.com/pages/publications/84883358899

U2 - 10.1016/j.clgc.2012.12.007

DO - 10.1016/j.clgc.2012.12.007

M3 - Journal article

C2 - 23332638

SN - 1938-0682

VL - 11

SP - 316

EP - 320

JO - Clinical Genitourinary Cancer (Online)

JF - Clinical Genitourinary Cancer (Online)

IS - 3

ER -

Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this